CINECA IRIS Institutional Research Information System

TARELLA, Corrado
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.507
EU - Europa 4.765
AS - Asia 2.132
AF - Africa 48
SA - Sud America 15
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 12.469
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.387
CN - Cina 1.213
DE - Germania 845
IE - Irlanda 569
UA - Ucraina 527
RU - Federazione Russa 499
SE - Svezia 483
FR - Francia 442
SG - Singapore 415
IT - Italia 382
FI - Finlandia 364
KR - Corea 311
AT - Austria 240
GB - Regno Unito 161
PL - Polonia 135
CA - Canada 114
VN - Vietnam 62
JP - Giappone 46
BE - Belgio 34
SN - Senegal 32
IN - India 28
TR - Turchia 14
ES - Italia 13
GR - Grecia 12
SA - Arabia Saudita 12
HK - Hong Kong 11
RO - Romania 11
DK - Danimarca 10
KE - Kenya 10
CH - Svizzera 9
NL - Olanda 8
BR - Brasile 7
BY - Bielorussia 7
ID - Indonesia 7
MX - Messico 5
NO - Norvegia 5
TW - Taiwan 5
CO - Colombia 4
JO - Giordania 3
LT - Lituania 3
PE - Perù 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
MU - Mauritius 2
UZ - Uzbekistan 2
AL - Albania 1
AR - Argentina 1
AU - Australia 1
BD - Bangladesh 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
EU - Europa 1
LU - Lussemburgo 1
MA - Marocco 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 12.469
Salva come PNG Salva come JPEG
Città #
Beijing 942
Chandler 916
Dublin 567
Jacksonville 333
Singapore 324
Villeurbanne 317
Houston 252
Santa Clara 247
Ann Arbor 244
Vienna 239
Medford 236
Princeton 195
Columbus 161
Dearborn 160
Ashburn 142
Nyköping 135
Warsaw 135
Fairfield 98
Milan 89
Wilmington 82
Torino 76
Woodbridge 60
San Mateo 59
Boston 57
Toronto 51
Boardman 49
Verona 47
Dong Ket 41
Redwood City 35
Norwalk 34
Nürnberg 34
Guangzhou 33
Ottawa 33
Brussels 31
Fremont 30
Seattle 28
Falls Church 25
Mountain View 24
Hefei 21
Lachine 20
New York 19
Kunming 18
Nanjing 17
Pisa 17
Shanghai 16
Washington 16
Los Angeles 14
Cambridge 13
Nanchang 13
Valdagno 13
Munich 12
Tokyo 12
Detroit 10
Kharkiv 10
Philadelphia 10
Pune 10
Jinan 9
Nairobi 9
Chengdu 8
Duncan 8
Redmond 8
San Diego 8
Tianjin 8
Zhengzhou 8
Baotou 7
Jakarta 7
Saint Petersburg 7
Wuhan 7
Düsseldorf 6
Leawood 6
Changsha 5
Chongqing 5
Hangzhou 5
Hebei 5
Palermo 5
Rome 5
Shenyang 5
Bari 4
Grafing 4
Naples 4
Orio Canavese 4
Taipei 4
Tappahannock 4
Taranto 4
Zurich 4
Amman 3
Bengaluru 3
Brunswick 3
Bucharest 3
Centro 3
Chicago 3
Craiova 3
Delhi 3
Edinburgh 3
Florence 3
Fuzhou 3
Helsinki 3
London 3
Lyon 3
Madrid 3
Totale 7.040
Salva come PNG Salva come JPEG
Nome #
Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. 571
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. 489
Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS 167
Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy 149
Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo) 148
High CR Rate and Prolonged EFS in aaIPI 2 – 3 Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) 148
Multiple courses of G-CSF in patients with decompensated cirrosi: consistent mobilization of immature cells ex pressing hepatocyte markers and exploratory clinical evaluation. 137
Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2–3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis 129
Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial 127
Multipotent Mesenchymal Stromal Stem Cell Expansion by Plating Whole Bone Marrow at a Low Cellular Density: A More Advantageous Method for Clinical Use 124
Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease 115
Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome 114
G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial) 113
Bone marrow transplantation for lymphoma CR1 112
Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients 111
Terminal differentiation of the human promyelocytic leukemia cell line, HL-60, in the absence of cell proliferation. 110
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. 110
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations 109
Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas 108
Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients 108
Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL) 107
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 105
Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival 102
Monoclonal gammopathy of undetermined significance coexisting in patients undergoing kidney transplantation does not adversely influence post-graft clinical outcome 102
Role of Na+/H+ exchange in the granulocyte-macrophage colony-stimulating factor-dependent growth of a leukemic cell line M07e. 100
Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders. 98
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study 98
The importance of the genetic picture and globin synthesis in determining the clinical and haematological features of thalassaemia intermedia. 97
Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes 97
Non-Hodgkin’s Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients 96
Monocytes of patients with Amyotrophic Lateral Sclerosis linked to gene mutations display altered TDP-43 subcellular distribution 96
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 95
Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis? 95
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. 93
CD34-positive cells: biology and clinical relevance. 92
Treatment options in skeletal localizations of hairy cell leukemia: A systematic review on the role of radiation therapy 91
Trophoblast cell line conditioned medium for in vitro culture and antigenic characterization of acute myeloid leukemia clonogenic cells. 91
Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines 91
The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation 91
Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment 91
GM-CSF-exposed peripheral blood progenitors as sole source of stem cells for autologous transplantation in two patients with multiple myeloma 89
Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting. 89
Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. 89
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome 86
Functional and phenotypic characterization of two HL60 clones resistant to dimethylsulfoxide. 86
Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. 85
Establishment from an adult leukemic patient of two novel precursor B cell lines with different growth modality. 84
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients 83
A phase I-II multicenter study on G-CSF in ALS: clinical and hematological results 83
Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. 83
Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. 83
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. 82
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF 82
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 81
MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study. 80
A pilot trial of G-CSF in amyotrophic lateral sclerosis 79
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 78
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders 77
Ras oncogene mutation in multiple myeloma. 77
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue 77
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 77
A single step density gradient separation for large scale enrichment of mobilized peripheral blood progenitor cells collected for autotransplantation. 76
Both early and committed progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. 75
Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. 75
LOW INCIDENCE AND SUCCESSFUL TREATMENT OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) AMONG 1649 PATIENTS UNDERGOING LIVER TRANSPLANTATION 75
MACOP-B for advanced stage large cell lymphoma (DLCL). More is better? Italian Multiregional Cooperative Study Group (IMCSGL). 74
High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma. 74
Stage II large B-cell lymphoma with sclerosis treated with MACOP-B. 73
G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. 72
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. 72
Immunological separation of two CFU-GM subsets showing different responsiveness to T-cell derived growth factors. 72
High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. 71
A short course of granulocyte-colony-stimulating factor to accelerate wound repair in patients undergoing surgery for sacrococcygeal pilonidal cyst: proof of concept 71
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. 71
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 70
Induction of differentiation of HL-60 cells by dimethyl sulfoxide: evidence for a stochastic model not linked to the cell division cycle. 69
Long-term molecular remission after conventional chemotherapy in a patient with Philadelphia-negative acute lymphoblastic leukemia. 69
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 69
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. 69
Combined administration of G-CSF and GM-CSF stimulates monocyte-derived pro-angiogenic cells in patients with acute myocardial infarction 68
Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. 68
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 67
Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial. 67
High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. 67
Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients 66
Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short interval between drug courses severely impair progenitor mobilization. 66
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial 66
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. 66
Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas 66
Bone marrow-derived cell mobilization by G-CSF to enhance osseointegration of bone substitute in high tibial osteotomy. 65
Minced umbilical cord fragments as a source of cells for orthopaedic tissue engineering: an in vitro study. Stem Cells Int. 2012;2012:326813. Epub 2012 Mar 7 64
Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case repor 64
Sensibilita' delle sottopopolazioni staminali mieloidi (CFU-GM) a CSA di diversa origine. 63
The aging effect of chemotherapy on cultured human mesenchymal stem cells 61
GIMEMA ALL 0183: a multicentric study on adult acute lymphoblastic leukaemia in Italy. 61
MACOP-B treatment for advanced stage diffuse large cell lymphoma: a multicenter Italian Study. 61
Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment. 60
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy 60
Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival 59
Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study 59
Totale 9.598
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.626
article - articoli 0
book - libri 0
conference - conferenze 5.090
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.716
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.118 0 0 0 0 83 294 227 59 133 140 131 51
2020/20211.128 149 29 90 49 84 46 130 34 205 129 72 111
2021/20221.427 26 27 40 72 41 40 164 58 31 144 305 479
2022/20232.864 288 188 66 220 225 620 188 155 252 509 87 66
2023/2024791 124 190 49 33 46 93 16 32 2 33 44 129
2024/20251.030 4 153 81 293 499 0 0 0 0 0 0 0
Totale 12.922